Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 66% Improvement Relative Risk c19hcq.org Purwati et al. HCQ for COVID-19 RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Double-blind RCT 240 patients in Indonesia Improved viral clearance with HCQ (p<0.000001) Purwati et al., Biochemistry Research Int., doi:10.1155/2021/6685921 Favors HCQ Favors control
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
Purwati et al., Biochemistry Research International, doi:10.1155/2021/6685921
Purwati et al., A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination.., Biochemistry Research International, doi:10.1155/2021/6685921
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 754 patients comparing HCQ+AZ along with other treatment groups using lopinavir/ritonavir and doxycycline to a control group taking AZ, finding significantly faster viral clearance with all treatment groups. (The labels in Figure 2 appear to be reversed).
risk of no viral clearance, 66.3% lower, RR 0.34, p < 0.001, treatment 38 of 121 (31.4%), control 111 of 119 (93.3%), NNT 1.6, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Purwati et al., 9 Feb 2021, Double Blind Randomized Controlled Trial, Indonesia, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Hindawi Biochemistry Research International Volume 2021, Article ID 6685921, 12 pages https://doi.org/10.1155/2021/6685921 Research Article A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/ Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections Purwati ,1,2 Budiono,2 Brian Eka Rachman,3 Yulistiani,3,4 Andang Miatmoko,1,3 Nasronudin,4 Soroy Lardo,5 Yongki Iswandi Purnama,5 Mafidhatul Laely,6 Ike Rochmad,7 Taufik Ismail,8 Sri Wulandari,8 Dwi Setyawan,3 Alfian Nur Rosyid,4 Herley Windo Setiawan,4 Prastuti Asta Wulaningrum,4 Tri Pudy Asmarawati ,4 Erika Marfiani,4 Shinta Karina Yuniati,4 Muhammad Rabiul Fuadi,4 Pepy Dwi Endraswari,4 Purwaningsih,4 Eryk Hendrianto,1 Deya Karsari,1 Aristika Dinaryanti,1 Nora Ertanti ,1 Igo Syaiful Ihsan,1 Disca Sandyakala Purnama,1 and Yuni Indrayani1 1 Stem Cell Research and Development Center, Airlangga University, Campus C UNAIR, Mulyorejo, Mulyosari, Surabaya 60115, Indonesia 2 Faculty of Vocational Studies, Airlangga University, Campus B UNAIR, Jl. Dharmawangsa Dalam Selatan, Gubeng, Surabaya 60286, Indonesia 3 Faculty of Pharmacy, Airlangga University, Nanizar Zaman Joenoes Building, Campus C UNAIR, Mulyorejo, Mulyosari, Surabaya 60115, Indonesia 4 Airlangga University Hospital, Campus C UNAIR, Mulyorejo, Mulyosari, Surabaya 60115, Indonesia 5 Gatot Soebroto Army Hospital, Jl. Abdul Rahman Saleh, Senen, Jakarta 10410, Indonesia 6 COVID-19 Isolation Center, Lamongan, Indonesia 7 Dustira Hospital, Jl. Dustira, Baros, Cimahi Tengah, Cimahi 40521, Indonesia 8 Polri Hospital, Jl. Raya Bogor, Kramat Jati, Jakarta 13510, Indonesia Correspondence should be addressed to Purwati; purwati@fk.unair.ac.id Received 4 November 2020; Revised 14 December 2020; Accepted 15 January 2021; Published 9 February 2021 Academic Editor: Zubeyir Huyut Copyright © 2021 Purwati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. At the present time, COVID-19 vaccines are at the testing stage, and an effective treatment for COVID-19 incorporating appropriate safety measures remains the most significant obstacle to be overcome. A strategic countermeasure is, therefore, urgently required. Aim. This study aims to evaluate the efficacy and safety of a combination of lopinavir/ritonavirazithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine used to treat patients with mild to moderate COVID-19 infections. Setting and Design. This study was conducted at four different clinical study sites in Indonesia. The subjects gave informed consent for their participation and were confirmed as being COVID-19-positive by means of an RTPCR test. The present study constituted a randomized, double-blind, and multicenter clinical study of patients diagnosed with mild to moderate COVID-19 infection. Materials and Methods. Six treatment groups participated in this study: a Control group administered with a 500 mg dose of azithromycin; Group A which received a 200/50 mg dose of lopinavir/ritonavir and 500 mg of azithromycin; Group B treated with a 200/50 mg dose of lopinavir/ritonavir and 200 mg of doxycycline; Group C administered with 200 mg of hydroxychloroquine and 500 mg of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit